Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice

Treating more with less: Effectiveness and event outcomes of antituberculosis fixed-dose combination drug versus separate-drug formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for pulmonary tuberculosis patients in real-world clinical practice

Introduction: Conventionally, a combination of four separate drugs (ethambutol, isoniazid, rifampicin, and pyrazinamide [EHRZ]) is the first-line pharmacotherapy for pulmonary tuberculosis (TB). In recent years, fixed-dose combination (FDC) formulation, where a single tablet contains the active ingr...

Full description

Bibliographic Details
Main Authors: Jacqueline Mui Lan Lai, Su Lan Yang, Richard Avoi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Journal of Global Infectious Diseases
Subjects:
Akurit-4
fixed-dose combination
intensive phase
propensity score
pulmonary tuberculosis
tuberculosis
Online Access:http://www.jgid.org/article.asp?issn=0974-777X;year=2019;volume=11;issue=1;spage=2;epage=6;aulast=Lai

Internet

http://www.jgid.org/article.asp?issn=0974-777X;year=2019;volume=11;issue=1;spage=2;epage=6;aulast=Lai

Similar Items